Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 ...
PETITE-T1D (clinical study identifier: NCT05757713) is an ongoing phase 4 single-arm, non-randomized, open-label, multicentre study designed to assess the safety and pharmacokinetics of Tzield in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback